Actelion Adding PAH Power With $420M CoTherix Buyout

Broadening its footprint in its key market of pulmonary arterial hypertension (PAH), while reducing its dependence on its Tracleer (bosentan) franchise, Actelion Ltd. entered a definitive agreement to acquire CoTherix Inc. for $13.50 per share, or about $420 million. (BioWorld Today)